Name: U.S. to start distributing Lilly COVID-19 antibody this week
Brand: reuters.com
SKU: reuters-com-1976
Availability: OnlineOnly

critic

U.S. to start distributing Lilly COVID-19 antibody this week

preview

By “Early treatment may help people avoid disease progression and avoid hospitalization,” Janet Woodcock, director of the Food and Drug Administration’s Center for Drug Evaluation and Research, said on a conference call along with Azar.The FDA on Monday gave emergency use authorization to Lilly’s antibody for anyone over age 65 who is recently diagnosed with mild-to-moderate COVID-19, and for patients age 12 and older who have an underlying health condition putting them at risk for serious illness. The agency said the treatment should not be used in patients already hospitalized with COVID-19.Bamlanivimab allocations to states and territories will be based on their number of hospitalized COVID-19 patients and the number of overall cases, government officials said on the HHS call.Woodcock explained that some states may have more people with underlying risk factors, such as obesity and diabetes. “Those are the people we are trying to target,” she said.A one-time infusion of bamlanivimab has been shown to reduce the risk of hospitalization and emergency room visits.The U.S. has purchased 300,000 doses of the treatment for this year and has an option to buy an additional 650,000 doses next year.Officials said out-of-pocket costs for patients covered by the government Medicare program but without supplemental insurance would be $60. That represents a 20% co-payment for the $300 infusion fee.Uninsured patients and those on Medicaid would have no financial responsibility, they said. Commercial insurance plans each have their own coverage terms.Reporting By Deena Beasley; Editing by Bill BerkrotOur Standards:

By “Early treatment may help people avoid disease progression and avoid hospitalization,” Janet Woodcock, director of the Food and Drug Administration’s Center for Drug Evaluation and Research, said on a conference call along with Azar.The FDA on Monday gave emergency use authorization to Lilly’s antibody for anyone over age 65 who is recently diagnosed with mild-to-moderate COVID-19, and for patients age 12 and older who have an underlying health condition putting them at risk for serious illness. The agency said the treatment should not be used in patients already hospitalized with...

public

Deena Beasley

Top and breaking news, pictures and videos from Reuters. For more breaking business news, follow @ReutersBiz.

reuters.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

U.S. to start distributing Lilly COVID-19 antibody this week

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS